Tags

Type your tag names separated by a space and hit enter

Endocannabinoid system dysfunction in mood and related disorders.
Acta Psychiatr Scand. 2011 Oct; 124(4):250-61.AP

Abstract

OBJECTIVE

The endocannabinoid (EC) system is widely distributed throughout the brain and modulates many functions. It is involved in mood and related disorders, and its activity may be modified by exogenous cannabinoids. This article examines the therapeutic potential of cannabinoids in psychiatric disorders.

METHOD

An overview is presented of the literature focussed on the functions of the EC system, its dysfunction in mood disorders and the therapeutic potential of exogenous cannabinoids.

RESULTS

We propose (hypothesize) that the EC system, which is homoeostatic in cortical excitation and inhibition, is dysfunctional in mood and related disorders. Anandamide, tetrahydrocannabinol (THC) and cannabidiol (CBD) variously combine antidepressant, antipsychotic, anxiolytic, analgesic, anticonvulsant actions, suggesting a therapeutic potential in mood and related disorders. Currently, cannabinoids find a role in pain control. Post mortem and other studies report EC system abnormalities in depression, schizophrenia and suicide. Abnormalities in the cannabinoid-1 receptor (CNR1) gene that codes for cannabinoid-1 (CB1) receptors are reported in psychiatric disorders. However, efficacy trials of cannabinoids in psychiatric disorders are limited but offer some encouragement.

CONCLUSION

Research is needed to elucidate the role of the EC system in psychiatric disorders and for clinical trials with THC, CBD and synthetic cannabinoids to assess their therapeutic potential.

Authors+Show Affiliations

Department of Psychiatry, University of Newcastle upon Tyne, Newcastle upon Tyne, UK. c.h.ashton@ncl.ac.ukNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

21916860

Citation

Ashton, C H., and P B. Moore. "Endocannabinoid System Dysfunction in Mood and Related Disorders." Acta Psychiatrica Scandinavica, vol. 124, no. 4, 2011, pp. 250-61.
Ashton CH, Moore PB. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand. 2011;124(4):250-61.
Ashton, C. H., & Moore, P. B. (2011). Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatrica Scandinavica, 124(4), 250-61. https://doi.org/10.1111/j.1600-0447.2011.01687.x
Ashton CH, Moore PB. Endocannabinoid System Dysfunction in Mood and Related Disorders. Acta Psychiatr Scand. 2011;124(4):250-61. PubMed PMID: 21916860.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Endocannabinoid system dysfunction in mood and related disorders. AU - Ashton,C H, AU - Moore,P B, Y1 - 2011/03/09/ PY - 2011/9/16/entrez PY - 2011/9/16/pubmed PY - 2012/1/27/medline SP - 250 EP - 61 JF - Acta psychiatrica Scandinavica JO - Acta Psychiatr Scand VL - 124 IS - 4 N2 - OBJECTIVE: The endocannabinoid (EC) system is widely distributed throughout the brain and modulates many functions. It is involved in mood and related disorders, and its activity may be modified by exogenous cannabinoids. This article examines the therapeutic potential of cannabinoids in psychiatric disorders. METHOD: An overview is presented of the literature focussed on the functions of the EC system, its dysfunction in mood disorders and the therapeutic potential of exogenous cannabinoids. RESULTS: We propose (hypothesize) that the EC system, which is homoeostatic in cortical excitation and inhibition, is dysfunctional in mood and related disorders. Anandamide, tetrahydrocannabinol (THC) and cannabidiol (CBD) variously combine antidepressant, antipsychotic, anxiolytic, analgesic, anticonvulsant actions, suggesting a therapeutic potential in mood and related disorders. Currently, cannabinoids find a role in pain control. Post mortem and other studies report EC system abnormalities in depression, schizophrenia and suicide. Abnormalities in the cannabinoid-1 receptor (CNR1) gene that codes for cannabinoid-1 (CB1) receptors are reported in psychiatric disorders. However, efficacy trials of cannabinoids in psychiatric disorders are limited but offer some encouragement. CONCLUSION: Research is needed to elucidate the role of the EC system in psychiatric disorders and for clinical trials with THC, CBD and synthetic cannabinoids to assess their therapeutic potential. SN - 1600-0447 UR - https://www.unboundmedicine.com/medline/citation/21916860/Endocannabinoid_system_dysfunction_in_mood_and_related_disorders_ L2 - https://doi.org/10.1111/j.1600-0447.2011.01687.x DB - PRIME DP - Unbound Medicine ER -